PT  - JOURNAL ARTICLE
AU  - Dong Wook Lee
AU  - Gun Oh Chong
AU  - Yoon Hee Lee
AU  - Dae Gy Hong
AU  - Young Lae Cho
AU  - Shin Young Jeong
AU  - Ji Young Park
AU  - Yoon Soon Lee
TI  - Role of SUV<sub>max</sub> and GLUT-1 Expression in Determining Tumor Aggressiveness in Patients With Clinical Stage I Endometrioid Endometrial Cancer
AID  - 10.1097/IGC.0000000000000301
DP  - 2015 Jun 01
TA  - International Journal of Gynecologic Cancer
PG  - 843--849
VI  - 25
IP  - 5
4099  - http://ijgc.bmj.com/content/25/5/843.short
4100  - http://ijgc.bmj.com/content/25/5/843.full
SO  - Int J Gynecol Cancer2015 Jun 01; 25
AB  - Objective The aim of this study was to determine the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in estimating tumor aggressiveness in patients with clinical stage I endometrial cancer and the correlation between aggressiveness and expression of glucose transporter 1 (GLUT-1).Methods 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed on 43 patients with clinical stage I endometrioid endometrial cancer. 18F-fluorodeoxyglucose uptake was quantified by calculating the maximum standardized uptake value (SUVmax) and GLUT-1 expression status based on immunohistochemistry.Results The mean (SD) SUVmax of the primary tumor was 8.55 (5.04). The mean SUVmax and GLUT-1 expression in stage IB and stage IC were significantly higher than that in stage IA (P = 0.001; P = 0.003). The mean (SD) SUVmax was 6.81 (4.55) in grade 1, 10.92 (4.61) in grade 2, and 15.35 (1.34) in grade 3 (grade 1 vs grade 2 and 3; P = 0.005). The mean (SD) GLUT-1 expression was 1.17 (0.94) in grade 1, 2.00 (0.94) in grade 2, and 3.00 (0.00) in grade 3 (grade 1 vs grade 2 and 3; P = 0.017).Conclusions Tumor aggressiveness, such as myometrial invasion or tumor grade, had a positive correlation with the SUVmax and GLUT-1 expression in patients with clinical stage I endometrioid endometrial cancer.